条件を付加する。<br>研究成果の公表にあたって謝辞の表明を必要とする。<br>RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. jellyfish EGFP cDNA, SV40 polyA, Phage P1 loxP site, mouse Nod2 genomic DNA Fluorescent Proteins/lacZ System INSERM INSERM true Card15 KO (C57BL/6N background) Card15 KO (C57BL/6N background) INSERM・Marco Giovannini。PGK-hygromycinカセットは除去済み。 B6.129-Nod2<tm1Jhgt> B6.129-Nod2<tm1Jhgt> Necessary documents for ordering:<ol><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol> C（3〜6か月） Developed by Marco Giovannini, INSERM. PGK-hygromycin cassette was removed by cre recombinase. In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.<br>RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.<br>In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters. Immunology and Inflammation Research C (3-6 months) Mouse Models for Human Disease Cre/loxP system RBRC01869 Card15 (Nod2) 遺伝子のノックアウトマウス。エクソン1をEGFPカセットで置換。GFPの発現は低い。C57BL/6背景 (RBRC01869) 、C57BL/6と129混合背景 (RBRC01941) 。 <a href='https://brc.riken.jp/mus/pcr01869'>Genotyping protocol -PCR-</a> Marco Giovannini Marco Giovannini This mouse was produced from the knock-in targeting of Card15 (Nod2) locus with EGFP cassette. The expression of the GFP is relatively low. C57BL/6 congenic (RBRC01869), C57BL/6 and 129 mixed background (RBRC01941). <A HREF="https://mus.brc.riken.jp/en/mouse_of_month/jun_2007_mm" target="_blank">Mouse of the Month Jun 2007</A> Internal/Organ Research Homozygote x Homozygote Homozygote x Homozygote